Orca Bio
Tuesday, June 04, 2024
Oncology
Company Presentation Theater 2
Orca Bio is a late-stage biotechnology company developing high-precision cell therapies for the treatment of cancer, autoimmune diseases and genetic blood disorders. Its investigational products are designed to safely replace a patient’s diseased blood and immune system with a healthy one, with the goal of delivering improved outcomes with dramatically fewer risks than the standard of care.
Our manufacturing platform uses single-cell precision to create purified, uniquely-defined products that have the potential to transform allogeneic cell therapy. At Orca Bio, our mission is to make curative cell therapies both more effective and safer, and in doing so, push past the field’s current boundaries and redefine its future.
Company Website:
https://orcabio.com/
Lead Product in Development:
Orca-T is a personalized investigational high-precision cell therapy for the treatment of acute myeloid leukemia (AML), myelodysplastic syndromes (MDS) and acute lymphocytic leukemia (ALL). Orca-T is designed to safely and effectively replace a patient’s diseased blood and immune system with a healthy one using highly purified stem cells, regulatory T cells and conventional T cells. Orca-T’s complex cellular manufacturing process controls for complexity, purification and potency of the cell products.
Orca-T is being evaluated in a pivotal Phase 3 trial called Precision-T which is expected to read out in the next year. In parallel, the company is advancing its pipeline with the goal of bringing cell therapy to all patients who could benefit, regardless of background or ability to identify a matched donor.
Company HQ City
Menlo Park
Company HQ State
CA
Company HQ Country
United States
CEO/Top Company Official
Ivan Dimov, PhD
Development Phase of Primary Product
Phase III
Primary Speaker
)
)
)
)
)
)
){kind=logo}
){kind=logo}
.png/fit-in/500x500/filters:no_upscale())